Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Higgins

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Cancer Research|February 13, 2013
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer modelsChristian Tovar, Bradford Graves, Kathryn Packman, et al.
Molecular Cancer Therapeutics|January 8, 2010
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor modelsSherif Daouti, Brian Higgins, Kenneth Kolinsky, et al.
Bioorganic & Medicinal Chemistry|June 15, 2005
RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluationLee A McDermott, Mary Simcox, Brian Higgins, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical DevelopmentZhuming Zhang, Xin-Jie Chu, Jin-Jun Liu, et al.
Nature Communications|January 21, 2024
Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML diseaseMary T Scott, Wei Liu, Rebecca Mitchell, et al.
Bioorganic & Medicinal Chemistry Letters|September 14, 2010
Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitorsJin-Jun Liu, Irena Daniewski, Qingjie Ding, et al.
Bioorganic & Medicinal Chemistry|July 7, 2014
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapyZhuming Zhang, Qingjie Ding, Jin-Jun Liu, et al.
Ebiomedicine|October 15, 2017
MDM2 Antagonists Counteract Drug-Induced DNA DamageAnna E Vilgelm, Priscilla Cobb, Kiran Malikayil, et al.
Journal of Medicinal Chemistry|July 2, 2013
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical developmentQingjie Ding, Zhuming Zhang, Jin-Jun Liu, et al.
Molecular Cancer Therapeutics|November 24, 2006
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trialsWanda DePinto, Xin-Jie Chu, Xuefeng Yin, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Cancer Research|February 13, 2013
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer modelsChristian Tovar, Bradford Graves, Kathryn Packman, et al.
Molecular Cancer Therapeutics|January 8, 2010
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor modelsSherif Daouti, Brian Higgins, Kenneth Kolinsky, et al.
Bioorganic & Medicinal Chemistry|June 15, 2005
RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluationLee A McDermott, Mary Simcox, Brian Higgins, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical DevelopmentZhuming Zhang, Xin-Jie Chu, Jin-Jun Liu, et al.
Nature Communications|January 21, 2024
Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML diseaseMary T Scott, Wei Liu, Rebecca Mitchell, et al.
Bioorganic & Medicinal Chemistry Letters|September 14, 2010
Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitorsJin-Jun Liu, Irena Daniewski, Qingjie Ding, et al.
Bioorganic & Medicinal Chemistry|July 7, 2014
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapyZhuming Zhang, Qingjie Ding, Jin-Jun Liu, et al.
Ebiomedicine|October 15, 2017
MDM2 Antagonists Counteract Drug-Induced DNA DamageAnna E Vilgelm, Priscilla Cobb, Kiran Malikayil, et al.
Journal of Medicinal Chemistry|July 2, 2013
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical developmentQingjie Ding, Zhuming Zhang, Jin-Jun Liu, et al.
Molecular Cancer Therapeutics|November 24, 2006
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trialsWanda DePinto, Xin-Jie Chu, Xuefeng Yin, et al.
Pageof 6